title: [Coronary heart disease - what is of importance after coronary intervention?].
abstract: In the European Union Ticagrelor has recently been approved, as another P2Y12-receptor antagonist in addition to clopidogrel and prasugrel, in [corrected] the drug treatment after coronary intervention. [corrected] Dual antithrombotic treatment must be given for 4 weeks after elective implantation [corrected] of bare-metal stents, or for at least 6 months [corrected] with acetylsalicylic acid (ASA) plus clopidogrel after implantation of a drug-eluding stent. After an acute coronary syndrome ASA and clopidogrel (or prasugrel or ticagrelor) must be given for 12 months. In patients requiring urgent oral anticoagulation essential triple-drug treatment should be given over as short a [corrected] space of time if possible. [corrected] Prasugrel and ticagrelor may, to protect against gastroduodenal bleeding, be given without restriction together with a proton-pump inhibitor. Preoperative coagulation management is essential for patients who have been on dual platelet-aggregation inhibitors, but premature withdrawal of this medication should be avoided.
authors.affiliation: Klinik für Kardiologie, Pneumologie, Angiologie Universitätsklinikum Düsseldorf. 40225 Düsseldorf. Tienush.Rassaf@med.uniduesseldorf.de
authors.forename: T
authors.initials: T
authors.lastname: Rassaf
authors.forename: C W
authors.initials: CW
authors.lastname: Hamm
mesh_terms: D000241:Adenosine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000359:Aftercare; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000008:administration & dosage*; D001241:Aspirin / Q000008:administration & dosage; D000077144:Clopidogrel; D003327:Coronary Disease / Q000628:therapy*; D004334:Drug Administration Schedule; D017277:Drug Approval; D004359:Drug Therapy, Combination; D054855:Drug-Eluting Stents; D006471:Gastrointestinal Hemorrhage / Q000139:chemically induced / Q000517:prevention & control; D006801:Humans; D009204:Myocardial Revascularization; D010879:Piperazines / Q000008:administration & dosage; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D000068799:Prasugrel Hydrochloride; D054328:Proton Pump Inhibitors / Q000008:administration & dosage; D015607:Stents; D013876:Thiophenes / Q000008:administration & dosage; D000077486:Ticagrelor; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000925:Anticoagulants; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D054328:Proton Pump Inhibitors; D013876:Thiophenes; D000077144:Clopidogrel; D000068799:Prasugrel Hydrochloride; D000077486:Ticagrelor; D000241:Adenosine; D013988:Ticlopidine; D001241:Aspirin